First randomized trial of resistance training on semaglutide and tirzepatide publishes its protocol
A 232-person trial will test directly whether strength training, protein supplements or both change muscle size in people taking semaglutide or tirzepatide, a question now answered only by extrapolation.
The protocol for the first randomized trial of resistance training in people taking semaglutide or tirzepatide was published in BMJ Open on April 22, 2026 [1]. The trial is called LEAN-PREP. It plans to enroll 232 adults and run for six months [1].
The study has four arms. Participants are randomized to a control group, a resistance exercise group, a protein supplementation group, or a group that does both resistance exercise and protein supplementation [1]. The primary outcome is quadriceps cross-sectional area measured on MRI [1]. Muscle cross-sectional area, rather than body weight or fat mass, is the endpoint the trial is built around [1].
Semaglutide is sold as Ozempic, Wegovy and Rybelsus. Tirzepatide is sold as Mounjaro and Zepbound. Both molecules are named in the trial's eligibility criteria [1].
Until this trial reports, exercise guidance for people using these medicines rests on extrapolation from research done in other populations, not on randomized results from people taking these drugs [1]. The protocol publication does not include any outcome data, so whether resistance training or protein supplementation changes muscle size in this group has not been established [1].
The published protocol does not report where participants will be recruited, how the trial is funded, what drug doses participants take, or when results are expected [1]. Those details have not been disclosed.
Why it matters for patients
Much of the public discussion about GLP-1 and dual-agonist weight-loss drugs centers on how much of the weight lost is lean tissue rather than fat. In people taking semaglutide or tirzepatide, that question has not been tested in a randomized trial of exercise [1]. LEAN-PREP is designed to produce that kind of evidence rather than adding another observational finding.
The four-arm design means the trial could separate the effect of lifting weights from the effect of protein supplementation, and could also test whether doing both together produces a different result than either alone [1]. That distinction matters because protein powders and gym memberships are the two most common things patients ask about, and right now there is no randomized trial in this population to point to [1].
The primary endpoint covers one muscle group, the quadriceps. Whether any findings would extend to other muscle groups or to measures such as strength, physical function or fall risk is not addressed by the stated primary outcome [1].
A six-month follow-up is long enough to measure a change in muscle cross-sectional area, but it will not show what happens over years of continuous treatment [1].
What happens next
The protocol is now on the record in BMJ Open as of April 22, 2026 [1]. The next visible milestones are enrollment of the planned 232 adults and completion of the six-month intervention period. A recruitment start date, a completion date and a target date for reporting results have not been reported [1].
Until those results appear, no randomized data exist on whether resistance training, protein supplementation, or the combination preserves quadriceps muscle size in adults taking semaglutide or tirzepatide [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.